Invention Grant
- Patent Title: MZB1, a novel B cell factor, and uses thereof
-
Application No.: US15689948Application Date: 2017-08-29
-
Publication No.: US10822401B2Publication Date: 2020-11-03
- Inventor: Rudolf Grosschedl , Henrik Flach , Sola Kim , Marlena Duchniewicz , Bernadette Schreiner , Marc Rosenbaum
- Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Applicant Address: DE Munich
- Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Current Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
- Current Assignee Address: DE Munich
- Agency: Leydig, Voit & Mayer, Ltd.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@52ef7423
- Main IPC: C07K14/435
- IPC: C07K14/435 ; C07K14/475 ; C12N5/10 ; C12N5/0781 ; G01N33/53 ; G01N33/566 ; G01N33/68 ; C07K16/18 ; A61K38/00

Abstract:
The marginal zone (MZ) and B1 subsets of B cells, which differ from conventional follicular (FO) B cells both developmentally and functionally, are involved in early responses to infectious pathogens and the production of self-reactive antibodies. A novel gene, mzb1, is expressed at high levels in MZ and B1 B cells but at low level, if at all, in FO B cells. MZB1 is involved in the regulation of proliferation, BCR-mediated signal transduction, and antibody production in B cells. Inhibitors, activators and enhancers of MZB1 expression or activity can be used as immune modulators for research and therapeutic purposes.
Public/Granted literature
- US20180057573A1 MZB1, A NOVEL B CELL FACTOR, AND USES THEREOF Public/Granted day:2018-03-01
Information query